Susceptibility of Mice to Trypanosoma evansi Treated with Human Plasma Containing Different Concentrations of Apolipoprotein L-1

Aleksandro S. Da Silva; Vinicius R. Fanfa; Mateus A. Otto; Lucas T. Gressler; Kaio C.S. Tavares; Cícera R. Lazzarotto; Alexandre A. Tonin; Luiz C. Miletti; Marta M. M. F. Duarte; Silvia G. Monteiro

추천

검색

질문

자료유형: 학술저널

저자정보: Aleksandro S. Da Silva (Universidade Federal de Santa Maria) Vinicius R. Fanfa (Universidade Federal de Santa Maria) Mateus A. Otto (Universidade Federal de Santa Maria) Lucas T. Gressler (Universidade Federal de Santa Maria) Kaio C.S. Tavares (Universidade do Estado de Santa Catarina) Cícera R. Lazzarotto (Universidade do Estado de Santa Catarina) Alexandre A. Tonin (Universidade Federal de Santa Maria) Luiz C. Miletti (Universidade do Estado de Santa Catarina) Marta M. M. F. Duarte (Lutheran University of Brazil - ULBRA) Silvia G. Monteiro (Universidade do Estado de Santa Catarina)

저널정보: 대한기생충학열대의학회 Parasites, Hosts and Diseases The Korean Journal of Parasitology Vol.49 No.4

발행연도: 2011.12

수록면: 427 - 430 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

The aim of this study was to test the susceptibility of mice to Trypanosoma evansi treated with human plasma containing different concentrations of apolipoprotein L-1 (APOL1). For this experiment, a strain of T. evansi and human plasma (plasmas 1, 2, and 3) from 3 adult males clinically healthy were used. In vivo test used 50 mice divided in 5 groups (A to E) with 10 animals in each group. Animals of groups B to E were infected, and then treated with 0.2 ml of human plasma in the following outline: negative control (A), positive control (B), treatment with plasma 1 (C), treatment with plasma 2 (D), and treatment with plasma 3 (E). Mice treated with human plasma showed an increase in longevity of 40.9±0.3 (C), 20±9.0 (D) and 35.6±9.3 (E) days compared to the control group (B) which was 4.3±0.5 days. The number of surviving mice and free of the parasite (blood smear and PCR negative) at the end of the experiment was 90%, 0%, and 60% for groups C, D, and E, respectively. The quantification of APOL1 was performed due to the large difference in the treatments that differed in the source plasma. In plasmas 1, 2, and 3 was detected the concentration of 194, 99, and 115 mg/dl of APOL1, respectively. However, we believe that this difference in the treatment efficiency is related to the level of APOL1 in plasmas.

#Trypanosoma evansi #mouse #treatment #human plasma #apolipoprotein-1

참고문헌 (24)

참고문헌 신청

1. [단행본] - Silva RAMS / 2002 / Trypanosoma evansi e Trypanosoma vivax: biologia diagnóstico e controle / Corumbá. Embrapa Pantanal : 166 ~

2. [학술지(정기간행물)] - Lun ZR / 1995 / Desser SS. Is the broad range of hosts and geographical distribution of Trypanosoma evansi attributable to the loss of maxicircle kinetoplast DNA / Parasitol Today 11 : 131 ~ 133

3. [단행본] - Hoare CA / 1972 / Trypanosomes of mammals: A zoological monograph / Oxford, UK. Blackwell Publ. Co : 749 ~

4. [단행본] - Kubiak GVL / 1954 / Tripanosomíase equina (Mal das Cadeiras). Boletim n.33. Instituto de Biologia e Pesquisas Tecnológicas do Estado do Paraná / Curitiba, Tip. João Haupt & Cia. Ltda : 72 ~

5. [학술지(정기간행물)] - Joshi PP / 2005 / Jannin J, Truc P. Human trypanosomosis caused by Trypanosoma evansi in India: The first case report / Am J Trop Med Hyg 73 : 491 ~ 495